The study found that patients receiving the combination of paclitaxel and bevacizumab had a significantly improved progression-free survival of 11.4 months, compared to 6.11 months with paclitaxel alone. This trend also suggested improved overall survival in patients treated with the new drug combination.
Gliadel Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma, increasing median survival to 13.9 months from 11.6 months. The treatment also shows a significant reduction in risk of death over the study period, with a 27% lower risk compared to placebo.
A study assessing H-pylori status in patients with gastric adenocarcinoma found that positive individuals had improved survival rates compared to those negative for the bacteria. The results suggest that H-pylori status can be a useful tool in clinical practice to distinguish between high and low risk patients.
Researchers found that adding neurotrophins to human embryonic stem cells increases cell survival by 36-fold. This discovery could enable mass production of stem cells for disease treatment and prevent tumor formation.
A study of 61,228 men aged 65 and older with local or regional stage prostate cancer found that lower socioeconomic status was significantly associated with decreased survival. Socioeconomic factors, including education level and community poverty, were the primary drivers of disparities in survival.
Researchers found that early identification of patients who would benefit from non-surgical treatment improved survival rates. The study, published in the Journal of Clinical Oncology, showed a significantly better cure rate when matching the right treatment to the patient's tumor biology.
A study of 2337 lung cancer patients with advanced disease found that nearly 1% survived for five years after receiving low-dose palliative radiation therapy, including 18 who achieved an apparent cure. Prognostic factors were not found to predict survival in these patients.
A study of 200 patients with head and neck cancer found that those with lower quality of life one year after treatment were more likely to die. The researchers discovered a correlation between steady-state QOL and long-term survival, suggesting that adjusting to the diagnosis and treatment may be crucial for better outcomes.
A study of over 1,000 male veterans found that prostate cancer screening with PSA testing did not prolong survival. Researchers compared men who died from prostate cancer to those living with the disease and found no difference in screening rates.
A study by Mayo Clinic researchers found that aggressive surgery greatly improves survival rates for patients with the most severe disease spread. Radical surgery was shown to improve five-year survival rates by 44% compared to non-radical surgery, indicating it aids in survival rather than increasing risk.
A seven-year study of over 400 patients found that delivering chemotherapy directly into the abdomen via a catheter increases survival and relapse-free survival rates compared to intravenous chemotherapy alone. However, side effects are significantly worse for the abdominal group.
A meta-analysis of 36 clinical trials reveals that optimal radiation therapy significantly improves patient survival rates in breast cancer patients. The analysis found a 2.9% and 6.4% absolute increase in survival at 5 and 10 years, respectively.
Researchers analyzed data from over 5,000 premature births and found that black baby girls were twice as likely to survive compared to white baby boys. Baby girls also had a significant survival advantage when born weighing less than 1,000 grams.
The Lancet is hosting a conference on child survival progress, focusing on reducing neonatal deaths by two-thirds by 2015. The event aims to provide opportunities for politicians and health-care workers to invest in proven interventions that can save one newborn life for every $2100 invested.
Researchers found that chemotherapy with doxorubicin and cisplatin extended disease-free survival by 50% and overall survival by 13% compared to radiation therapy. Serious side effects were more common in the chemotherapy group, but a new regimen may be less toxic.
Research reveals that highly stimulated brain cells reactivate dormant survival genes, making them healthier and more resilient. This discovery holds implications for developing therapies to halt neurological diseases like Alzheimer's and Parkinson's, as well as mitigating the effects of maternal substance abuse on unborn babies.
A phase III clinical trial found that combining gemcitabine with capecitabine significantly improves overall survival for patients with locally advanced or metastatic pancreatic cancer. The combination of treatments resulted in a median survival of 7.4 months compared to 6 months with gemcitabine alone.
A new vaccine-based approach has been shown to prolong disease progression in patients with renal cancer and malignant melanoma. The therapy, which uses latex or silica beads, was found to stabilise and control disease for an average of one year. In contrast, standard treatments have limited efficacy and are often toxic.
Research from ECCO 13 emphasizes the importance of cervical cancer detection, treatment, and prevention. The study found that adequate radiotherapy significantly improves survival rates for women with cervical cancer, particularly in sub-Saharan Africa where HIV co-infection does not impact survival. The data also highlights the need f...
Researchers found that women with lung cancer have a significantly better cancer-specific, overall, and relative survival rate compared to men. In treated patients, women had a 54% lung cancer specific 5-year survival rate, while in untreated patients, women lived longer than men by 21%.
New therapy Iressa shows no significant survival improvement for NSCLC patients, but offers better outcomes for Asian and non-smoking patients. The study results provide insight into the effectiveness of EGFR inhibitors in specific patient groups.
A study of 1901 women with early-stage breast cancer found that longer tamoxifen treatment periods resulted in improved overall survival, particularly in younger patients. Women aged 50-55 showed significant overall survival improvement after five years of treatment.
Recent studies have shown that combining standard chemotherapy with new monoclonal antibody therapies can significantly improve survival rates for patients with follicular lymphoma. The latest study, led by Richard I. Fisher, found a 91% four-year survival rate for patients treated with this regimen.
A clinical trial has found that a new treatment regimen combining radiation therapy with concurrent chemotherapy significantly increases the probability of survival for patients with recurrent squamous-cell head and neck cancer. The study showed improved one-year and two-year survival rates compared to standard chemotherapy treatment, ...
Treating four or more brain tumors with radiosurgery is safe and effective, translating to a survival benefit of up to 18 months for some patients. The study's findings suggest that tumor volume rather than the number of brain metastases should be used as a criterion for radiosurgery.
Researchers found that gene therapy using manganese superoxide dismutase plasmid liposome (MnSOD-PL) protected healthy tissue from damage during and after radiation retreatment. The therapy significantly improved survival rates and reduced side effects in lung cancer patients.
A new study from Fox Chase Cancer Center found that married breast cancer patients do not have different survival rates than unmarried women. However, younger women and those over 70 tend to fare worse despite similar disease characteristics and treatment factors. Age emerged as a significant predictor of relapse-free survival.
A study by Mayo Clinic researchers found that radical surgery significantly improves five-year survival rates for patients with ovarian cancer and diaphragm disease. The procedure resulted in a 55% survival rate compared to 28% for those who did not undergo surgery.
A study of 906 breast cancer patients found that comorbidities such as diabetes and hypertension contributed to racial disparities in survival rates. Black patients had shorter overall survival rates, while whites were more likely to die from competing causes.
Researchers found that women taking letrozole experienced a significantly better overall disease-free survival rate and distant disease-free survival rate compared to those on placebo. This study confirms the protective effect of extended adjuvant letrozole therapy for postmenopausal breast cancer patients.
Researchers found that immediate postoperative radiotherapy significantly improved biochemical progression-free survival for patients at risk of relapse, with a 74% success rate compared to 53%. Long-term follow-up is needed to assess its effects on distant metastases and survival.
A study published in Cancer journal found that tumor size decreased significantly between 1975 and 1999, explaining 61% of the increased survival rate in localized breast cancer. Adjusting for tumor size diminished the magnitude of the survival increase within each stage category.
A recent study found that patients with complete revascularization have significantly better long-term outcomes and a 70% lower chance of death within five years. The study also suggests using arterial grafts instead of veins for improved patient survival.
A Harvard Medical School study reveals that phosphatases play a crucial role in regulating cell survival and chemoresistance. The researchers identified tumor suppressor phosphatases whose loss of function leads to chemoresistance, providing potential new targets for cancer treatment.
A study by Texas A&M AgriLife Communications reveals that planting containerized seedlings in the fall can significantly increase the survival rate of pine tree seedlings, with a 93% survival rate compared to 67%. The shift in reforestation methods may help landowners improve their forest land management and reduce waste.
A study by the University of California - Davis Health has demonstrated a significantly improved survival rate for locally advanced lung cancer patients using a chemotherapy regimen that includes docetaxel. The study showed a five-year survival rate of 29 percent, surpassing previous results.
A randomized trial found that the ALL-2 regimen of cytarabine with high-dose mitoxantrone improved complete remission rates and survival outcomes for patients with acute lymphocytic leukemia. The regimen demonstrated a significant survival advantage, particularly in patients with the Philadelphia chromosome genetic predisposition.
Researchers found that ablation therapy extended median survival to 33 months compared to 20 months for chemotherapy-only treatment. The study also showed improved disease recurrence rates and overall 3-year survival rate of 51%.
A national population-based study of 16,036 lung cancer patients found that Hispanics with curable stage I lung cancer had poorer lung cancer specific survival rates and worse all-cause mortality than white persons. This disparity was largely explained by lower surgical resection rates among Hispanics and a higher probability of being ...
A recent Mount Sinai study found that Hispanic patients with stage I non-small cell lung cancer have a significantly lower five-year survival rate of 54% compared to white patients at 62%. This disparity is largely attributed to unequal access to surgical resection, as well as higher rates of advanced-stage diagnosis.
Researchers at Vanderbilt University Medical Center found that adding bevacizumab to standard chemotherapy extended median survival by 2.3 months, improving overall tumor response rates and progression-free survival. This new treatment regimen is recommended as the standard for advanced non-small cell lung cancer patients.
A combination of chemotherapy drugs showed improved overall and progression-free survival rates compared to a single drug, gemcitabine. Patients treated with the combination regimen (PEGF) had a higher percentage alive without disease after 4 months than those on standard treatment.
A clinical trial found that systematic aortic and pelvic lymphadenectomy improved progression-free survival, but not overall survival, in patients with advanced ovarian cancer. The procedure did not significantly increase median overall survival duration.
Research on almost 116,000 English and Welsh breast cancer patients found that South Asian women were diagnosed at a significantly younger age, averaging 52 compared to 63 for other women. Additionally, their five-year survival rate was over 70%, with affluence boosting health and survival rates even among the poor.
Researchers found that freedom from rejection after 12 months was 10% higher with those treated with CellCept (63%) compared to azathioprine (53%). Additionally, the one-year survival rate was significantly better in CellCept patients (96%), compared to only 87% of AZA patients.
A pivotal study found that CyIS significantly reduces chronic rejection and prolongs survival in lung-transplant recipients, offering hope for a breakthrough therapy to address this unmet need. The study demonstrated an 84% four-year survival rate with CyIS compared to 56% with placebo.
A meta-analysis of 27 clinical trials found that erythropoietin treatment lowers the likelihood of needing a blood transfusion and improves hematologic response in cancer patients. However, results on overall survival are inconclusive, suggesting erythropoietin should not be used to increase survival outside clinical trials.
Participation in cancer clinical trials improves survival, with significant benefits for Kaposi Sarcoma patients. Young adults with sarcomas face limited treatment options and low clinical trial participation rates, contributing to poor survival rates.
A study of liver transplant patients found that older donors, longer cold ischemia times, and urgent recipient status are significant risk factors for shortened graft survival. The results suggest a new model to predict post-transplant survival, potentially improving organ allocation decisions.
A study of liver transplant patients with hepatitis C found that donor age does not impact long-term survival rates. Instead, maintenance azathioprine was associated with improved overall and 3-month survival rates, suggesting a complex relationship between immunosuppression and disease progression.
A recent study found that Medicaid patients diagnosed with late-stage cancer have significantly poorer survival rates than those diagnosed earlier. The median survival was 18 months for late enrollers compared to 38 months for early enrollers and non-Medicaid patients.
Researchers discovered that DJ-1 negatively regulates PTEN function, suggesting a potential link between high DJ-1 levels and enhanced cancer cell survival. Elevated DJ-1 levels were associated with poor prognosis in lung cancer patients and may serve as a prognostic marker for cancer patients.
St. Jude Children's Research Hospital finds that upfront treatment with radiation followed by chemotherapy can cure brain tumors in children over 3 years old, raising survival rates to 78% for two-year event-free survival and 89% for overall survival. The study shows promise for treating relapse cases using ICE chemotherapy.
Researchers found that overweight patients, those with moderate income, and women survived longer with esophageal and stomach cancer. Premature birth significantly increases the risk of esophageal adenocarcinoma, potentially linked to gastroesophageal reflux disease.
Research findings indicate that increased sun exposure is associated with improved melanoma survival, while decreased UV radiation exposure may lower non-Hodgkin lymphoma risk. These studies provide new evidence for the potential beneficial effects of sunlight on cancer incidence and outcome.
A European study has found a persistent three-decade increase in childhood cancer incidence, with rising rates in all tumour types. The study also shows that survival rates have improved substantially over the past three decades, with 5-year actuarial survival rates reaching 75% for children in western Europe.
Researchers analyzed 191 untreated follicular lymphoma patients and developed a model that divides patients into four groups with disparate average survival rates. The model uses gene expression patterns from non-malignant immune cells to predict patient risk, suggesting new therapeutic approaches.
Researchers found a correlation between the presence of the CXCR3 protein and increased survival in Stage III metastatic melanoma patients. This discovery may lead to improved vaccines that 'turn-on' cancer-killing immune cells and instruct them to find tumors.
A randomised clinical trial found that post-operative radiotherapy significantly improved biological and clinical progression-free survival in men with high-risk prostate cancer. The study showed a clear benefit in terms of biological progression-free survival for men who received radiotherapy treatment in addition to surgery.
A Fox Chase Cancer Center study found IMRT to be cost-effective for men with intermediate-risk prostate cancer, improving quality-adjusted survival and reducing the need for additional treatments. The study's findings suggest that IMRT may offer better value compared to traditional conformal radiotherapy.